We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
TODAY'S HIGH
4299.1
TODAY'S LOW
3975
52 WEEK HIGH
5614.6
52 WEEK LOW
3654
% of Shares Held by
All Insider
8.29%
% of Shares Held by
Institutions
66.33%
% of Float Held by
Institutions
72.32%
Number of Institutions
Holding Shares
187
MARKET CAP
70166.61 Cr.
ETERPRISE VALUE
69363.95 Cr.
NO. OF SHARES
16.59 Cr.
BOOK VALUE
1149.694
DIV. YIELD
25%
DEBT
3384.50 Cr.
GROSS PROFIT
11384 Cr.
CASH
4436.50 Cr.
REVENUE
21439.09 Cr.
REVENUE/SHARE
1292.459
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | -1120.10 Cr. | 411 Cr. | -21.40 Cr. | -228.20 Cr. |
| Change To Liabilities | 441.20 Cr. | 286.10 Cr. | 157.60 Cr. | 39.80 Cr. |
| Total cashflows from Investing Activities | -2638.70 Cr. | -2266 Cr. | -492.30 Cr. | -772.70 Cr. |
| Net Borrowings | 273.50 Cr. | 609.40 Cr. | -1916.50 Cr. | -1518.20 Cr. |
| Total Cash from Financing Activities | -242.20 Cr. | -29.80 Cr. | -2515.90 Cr. | -2132.60 Cr. |
| Other Liabilities | 401.40 Cr. | -325.80 Cr. | 482.10 Cr. | 412.20 Cr. |
| Total Assets | 33.40 Cr. | 26.90 Cr. | 40 Lakhs | 40 Lakhs |
| Net Income | 2356.80 Cr. | 1723.80 Cr. | 1949.80 Cr. | 1879.50 Cr. |
| Change in Cash | 3.20 Cr. | 1285.80 Cr. | -26.60 Cr. | -31.40 Cr. |
| Effect of Exchange Rate | 73.30 Cr. | 11.30 Cr. | -2.50 Cr. | 3.50 Cr. |
| Total Cash from Operating Activities | 2810.80 Cr. | 3570.30 Cr. | 2984.10 Cr. | 2870.40 Cr. |
| Depreciation | 1182.40 Cr. | 1279.60 Cr. | 1247.20 Cr. | 1219 Cr. |
| Other Cashflows from Investing Activities | 87.30 Cr. | 122 Cr. | 101.60 Cr. | 78.10 Cr. |
| Dividends Paid | -414.60 Cr. | -414.70 Cr. | -331.40 Cr. | -332 Cr. |
| Change to Inventory | -532.80 Cr. | -988.10 Cr. | -148.70 Cr. | -448 Cr. |
| Change to Account Receivables | -1701.20 Cr. | 208.10 Cr. | -1244.60 Cr. | 179.70 Cr. |
| Other Cashflows from Financing Activities | -134.50 Cr. | -132.10 Cr. | -221 Cr. | -228.90 Cr. |
| Change to Net Income | 663 Cr. | 1386.60 Cr. | 540.70 Cr. | -411.80 Cr. |
| Capital Expenditures | -1466 Cr. | -974.10 Cr. | -484.60 Cr. | -695.50 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | 1748.20 Cr. | 1654.10 Cr. | 1541 Cr. | 1560.70 Cr. |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 3229.80 Cr. | 2641.30 Cr. | 1803.20 Cr. | 2244.30 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 3151.60 Cr. | 3297 Cr. | 2931.30 Cr. | 1967.50 Cr. |
| Selling General Administrative | 6208.10 Cr. | 5459 Cr. | 5012.90 Cr. | 4868 Cr. |
| Gross Profit | 11384 Cr. | 10307.70 Cr. | 9400.90 Cr. | 8343 Cr. |
| Ebit | 3151.60 Cr. | 3297 Cr. | 2931.30 Cr. | 1967.50 Cr. |
| Operating Income | 3151.60 Cr. | 3297 Cr. | 2931.30 Cr. | 1967.50 Cr. |
| Other Operating Expenses | 276.10 Cr. | -102.40 Cr. | -84.30 Cr. | -53.20 Cr. |
| Interest Expense | -95.80 Cr. | -97 Cr. | -98.30 Cr. | -88.90 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 873 Cr. | 917.50 Cr. | -146.60 Cr. | 364.80 Cr. |
| Total Revenue | 21439.10 Cr. | 18972.20 Cr. | 17460 Cr. | 15385.10 Cr. |
| Total Operating Expenses | 18287.50 Cr. | 15675.20 Cr. | 14528.70 Cr. | 13417.60 Cr. |
| Cost of Revenue | 10055.10 Cr. | 8664.50 Cr. | 8059.10 Cr. | 7042.10 Cr. |
| Total Other Income Expense Net | 78.20 Cr. | -655.70 Cr. | -1128.10 Cr. | 276.80 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 2356.80 Cr. | 1723.80 Cr. | 1949.80 Cr. | 1879.50 Cr. |
| Net Income Applicable to Common Shares | 2356.80 Cr. | 1723.80 Cr. | 1949.80 Cr. | 1879.50 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 2724.60 Cr. | 3564.80 Cr. | 2765.90 Cr. | 4436.70 Cr. |
| Capital Surplus | 928 Cr. | 888.70 Cr. | 849.50 Cr. | 821.10 Cr. |
| Total Liabilities | 10612.70 Cr. | 9242.90 Cr. | 7725.30 Cr. | 8523 Cr. |
| Stock Holder Equity | 19052.70 Cr. | 17306.20 Cr. | 15498.80 Cr. | 14019.70 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 4417.10 Cr. | 1487.70 Cr. | 1281.90 Cr. | 920.60 Cr. |
| Total Assets | 29665.40 Cr. | 26549.10 Cr. | 23224.10 Cr. | 22542.70 Cr. |
| Common Stock | 83.20 Cr. | 83.20 Cr. | 83.10 Cr. | 83 Cr. |
| Retained Earnings | 17646.70 Cr. | 15734.90 Cr. | 14424.70 Cr. | 12864.60 Cr. |
| Other Liabilities | 253.90 Cr. | 273.90 Cr. | 313.50 Cr. | 353 Cr. |
| Good Will | 441.80 Cr. | 456.80 Cr. | 399.40 Cr. | 390.20 Cr. |
| Treasury Stock | 394.80 Cr. | 599.40 Cr. | 141.50 Cr. | 251 Cr. |
| Other Assets | 1372.90 Cr. | 1158.20 Cr. | 1479.50 Cr. | 522.70 Cr. |
| Cash | 1485.20 Cr. | 1482.90 Cr. | 205.30 Cr. | 222.80 Cr. |
| Current Liabilities | 9784.20 Cr. | 8339.10 Cr. | 7281.40 Cr. | 5970 Cr. |
| Long Term Asset Charges | 1278.10 Cr. | 1063 Cr. | 1221.40 Cr. | 416.80 Cr. |
| Short Long Term Debt | 0 | 0 | 378.30 Cr. | 419.90 Cr. |
| Other Stockholder Equity | 554.90 Cr. | 796.10 Cr. | 242.10 Cr. | 304.50 Cr. |
| Property Plant Equipment | 6216.90 Cr. | 5711.10 Cr. | 5233.20 Cr. | 5408.80 Cr. |
| Total Cur. Assets | 18110.60 Cr. | 14824.90 Cr. | 13037 Cr. | 11450.10 Cr. |
| Long Term Investments | 798.60 Cr. | 833.30 Cr. | 309.10 Cr. | 334.20 Cr. |
| Net Tangible Assets | 15886.30 Cr. | 13284.60 Cr. | 12333.50 Cr. | 9192.80 Cr. |
| Short Term Investments | 2951.30 Cr. | 1974.40 Cr. | 2368.70 Cr. | 2252.90 Cr. |
| Net Receivables | 7004.90 Cr. | 5445.60 Cr. | 5730.90 Cr. | 4563.20 Cr. |
| Long Term Debt | 574.60 Cr. | 380 Cr. | 0 | 2144.80 Cr. |
| Inventory | 5088.40 Cr. | 4541.20 Cr. | 3506.60 Cr. | 3357.90 Cr. |
| Accounts Payable | 2557.20 Cr. | 1269.60 Cr. | 1074.50 Cr. | 1029.60 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account